Protocols›Immune & organ›Post-COVID & CIRS
← Protocols
Has approved analogues · off-label hereRU-registered · public clinical useNo approved clinical use

Post-COVID & CIRS

Stack: KPV + BPC-157 + Thymosin α-1 + Semax · post-viral recovery
"An immune-recovery pattern anchored on Thymosin α-1, which has genuine international clinical use. The four-compound combination, though, is unstudied — real parts, untested whole."
GoalPost-viral recovery
Compounds4 · KPV + BPC-157 + Thymosin α-1 + Semax
Humans exposed (est.)High (Thymosin α-1 clinical)
StatusThymosin α-1 approved in ~35 countries · Semax registered in Russia · BPC-157/KPV: research material · the combination is unstudied
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Has approved analogues
Where / who
Community / athlete and clinic use as tagged above.
Use status
Thymosin α-1: broad international clinical use.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
KPV / BPC-157 / Thymosin α-1: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing disrupted legitimate compounding — see the regulatory layer for current status.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Real for Thymosin α-1; combination unstudied.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Regulatory — read carefully
FDA (US)
Thymosin α-1 is not FDA-approved; it is approved in ~35 other countries.
MHRA (UK)
Not licensed in the UK.
What it means
International approval of one component is not approval of the stack.
Why it matters
The combination has no trial; treat component evidence and stack evidence separately.
Basis: Thymosin α-1 marketing authorisations (~35 countries) · Semax Russian register
Why this combination

Thymosin α-1 is approved in ~35 countries and carries real immune-modulation use; Semax is Russian-registered. BPC-157/KPV are research material. The individual provenance is unusually strong for this site — but the combination itself is unstudied.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription. Specific timing is part of membership.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake High

Thymosin α-1: broad international clinical use.

Human efficacy Mixed

Real for Thymosin α-1; combination unstudied.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Strong components, unstudied as a stack.

Fast facts
Compounds

KPV · BPC-157 · Thymosin α-1 · Semax

Humans exposed (est.)

High (Thymosin α-1 clinical).

UK strip

GREEN — research material